Breaking News

Evonik to Restructure Keto and Pharma Amino Acid Business

To develop the business in France and China and discontinue production of keto acids in Germany.

Evonik is restructuring to focus on its strategic core growth areas. Evonik will evaluate strategic options, such as partnerships or divestment, for developing its keto and pharma amino acid production sites in Ham and Wuming. It is also planning to discontinue its production of keto acids in Hanau by the end of 2025, affecting around 260 colleagues. Evonik’s keto and pharma amino acid business generates an annual average revenue of around 100 million euros.
 
As part of Evonik’s life sciences division, Nutrition & Care, the Health Care business is transforming to focus on its growing core areas of expertise. These include complex and highly potent active pharmaceutical ingredients (APIs), oral and injectable drug delivery, and precision biosolutions such as lipids for mRNA and gene delivery, and cell culture ingredients.
 
“This is the start of a new chapter in our transformation. Social responsibility is in our core. We will support all the affected colleagues and try to find the best solution for each person. I am confident our new chapter will focus our Health Care business, and empower our customers to pioneer innovation,” said Thomas Wessel, Chief Human Resources Officer and Labor Relations Director.
  
“Our colleagues in Hanau have contributed to saving lives by making active pharmaceutical ingredients. Finding a good home for our employees is close to my heart. At the same time, our Health Care business will now be able to focus all energy and resources on future technologies to better serve our customers and accelerate growth,” said Yann d’Hervé, Head of the Health Care business line.
 
Keto acids are used as active pharmaceutical ingredients (APIs). Pharma amino acids and their derivatives have various applications such as in medical nutrition, cosmetics, human nutrition, APIs, and pharmaceutical intermediates.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters